Changes in cell growth and metabolism are affected by the surrounding environmental factors to adapt to the cell’s most appropriate growth model. However, abnormal cell metabolism is correlated with the occurrence of many diseases and is accompanied by changes in galectin (Gal) performance. Gals were found to be some of the master regulators of cell–cell interactions that reconstruct the microenvironment, and disordered expression of Gals is associated with multiple human metabolic-related diseases including cancer development. Cancer cells can interact with surrounding cells through Gals to create more suitable conditions that promote cancer cell aggressiveness. In this review, we organize the current understanding of Gals in a systematic ...
Galectins are a group of proteins that bind β-galactosides through evolutionarily conserved sequence...
Galectins are a family of animal lectins with diverse biological activities. They function both extr...
The efficacy of cancer immunotherapy is limited, in part, by the multitude of immunosuppressive mech...
The galectins are a family of proteins that are distributed widely in all living organisms. All of t...
In the last decades, the focus of cancer research has moved from epithelial cells to the tumor milie...
Galectins are glycan-binding proteins implicated in intracellular signaling, cell-cell communication...
In the post-genomic era, many efforts have been devoted to better understanding the biological infor...
Galectins constitute an evolutionary conserved family that binds to β-galactosides. There is growing...
Galectins are glycan‐binding proteins implicated in several biological activities such as intracellu...
Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal tumor types, with extremely lo...
Evasion of immune surveillance is an accepted hallmark of tumor progression. The production of immun...
International audienceAlthough we witnessed considerable progress in the prevention and treatment of...
Galectins (Gals) are evolutionarily conserved proteins that bind to β-galactoside containing glycans...
Galectins are glycan-binding proteins that contain one or two carbohydrate domains and mediate multi...
The cell surface is covered by different oligosaccharides, which are anchored in the plasmatic membr...
Galectins are a group of proteins that bind β-galactosides through evolutionarily conserved sequence...
Galectins are a family of animal lectins with diverse biological activities. They function both extr...
The efficacy of cancer immunotherapy is limited, in part, by the multitude of immunosuppressive mech...
The galectins are a family of proteins that are distributed widely in all living organisms. All of t...
In the last decades, the focus of cancer research has moved from epithelial cells to the tumor milie...
Galectins are glycan-binding proteins implicated in intracellular signaling, cell-cell communication...
In the post-genomic era, many efforts have been devoted to better understanding the biological infor...
Galectins constitute an evolutionary conserved family that binds to β-galactosides. There is growing...
Galectins are glycan‐binding proteins implicated in several biological activities such as intracellu...
Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal tumor types, with extremely lo...
Evasion of immune surveillance is an accepted hallmark of tumor progression. The production of immun...
International audienceAlthough we witnessed considerable progress in the prevention and treatment of...
Galectins (Gals) are evolutionarily conserved proteins that bind to β-galactoside containing glycans...
Galectins are glycan-binding proteins that contain one or two carbohydrate domains and mediate multi...
The cell surface is covered by different oligosaccharides, which are anchored in the plasmatic membr...
Galectins are a group of proteins that bind β-galactosides through evolutionarily conserved sequence...
Galectins are a family of animal lectins with diverse biological activities. They function both extr...
The efficacy of cancer immunotherapy is limited, in part, by the multitude of immunosuppressive mech...